Intellia Therapeutics Reports Reduced Q1 Net Loss, Extends Cash Runway into 2028 After Successful $194.6M Offering
NTLA has more than doubled off its 52-week low of $6.83.
Summary
Intellia Therapeutics reported a reduced net loss in Q1 2026 and significantly extended its cash runway into 2028 following a successful $194.6 million public offering, capitalizing on recent positive clinical trial data.
Key Events · Earnings and Guidance · NTLA
-
Reduced Net Loss
Net loss for Q1 2026 decreased to $96.2 million from $114.3 million in Q1 2025, primarily due to a $27.7 million reduction in R&D expenses.
-
Extended Cash Runway
The company now expects its cash, cash equivalents, and marketable securities, including proceeds from the recent equity offering, to fund operations at least into 2028, an extension from the previously reported second half of 2027.
-
Successful Public Offering
Subsequent to the quarter end, Intellia closed a public offering on April 30, 2026, raising approximately $194.6 million in net proceeds by selling 19,255,815 shares at $10.75 per share. This offering was initiated shortly after positive Phase 3 clinical data.
-
Ongoing At-The-Market (ATM) Program Activity
During Q1 2026, the company issued 2,612,344 shares through its ATM program for net proceeds of $33.6 million at an average price of $13.21 per share. As of March 31, 2026, $368.5 million remains available under the amended ATM program.
Analysis · NTLA · Life Sciences
Intellia Therapeutics' Q1 2026 report highlights a significant reduction in net loss to $96.2 million, down from $114.3 million in the prior year, driven by decreased research and development expenses. Crucially, the company's liquidity position has been substantially strengthened by a recent $194.6 million net proceeds public offering in April 2026, extending its cash runway to at least into 2028. This capital raise follows highly positive Phase 3 clinical trial results for its gene-editing therapy, lonvo-z, and the lifting of clinical holds on its nex-z trials, providing critical funding for commercialization preparations and ongoing pipeline development.
At the time of this filing, NTLA was trading at $13.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $6.83 to $28.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.